
Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
IN VIVO
Start-Up
The RPM Report
Medtech Insight
Sign up
now
|
|

September 21-23, 2010 • New York City
More information on the 2010 event to be announced shortly.
Save the date in your Microsoft Outlook Calendar
|
|
|
|
|
Early Bird Discount $400 (exp.
4/30/10)
Individual
Registration: Reg. $1995
Company Registration: Reg. $1795 3 or more attendees, each
Cancellation Policy
|
|
|
|
|
|
|
Thank you to all the attendees, speakers and sponsors who helped make PSA 2009 a resounding success!
NEW PROGRAM and VENUE FOR 2009!
- 1:1 interview with Schering-Plough's CEO Fred Hassan
- 1:1 fireside chat with GSK's Head of R & D, Moncef Slaoui
- 11+ networking opportunities with the most senior level executives in the biopharma business
- 3 FREE pre-conference workshops
- 27+ strategies from pharma heads of R & D, BD, CFOs,
CEOs and corporate VCs
- 25+ deal case studies, biotech investing, M&A, health
reform, and more! Complete schedule available here.
WHY ATTEND PSA?
Simple. Meet the most important people in the business.
Beyond the basics! Windhover is proud to present the ONLY conference that delivers 100% case studies by CEOs and senior executives in the industry. Don’t miss insight from the following strategists, including:
Fred Hassan
CEO
Schering-Plough Corporation
Frank D’Amelio
CFO
Pfizer
David Mott
General Partner
New Enterprise Associates
Former MedImmune CEO
Elliott Sigal, MD, PhD
EVP, CSO, President, Research and Development
Bristol-Myers Squibb
Martin MacKay
President of Pfizer Global Research & Development
Pfizer
Michael Diem, MD
Partner
SR One/Glaxosmithkline
Vincent Aurentz
Executive Vice President, Portfolio Development
Merck Serono |
Mervyn Turner
Chief Strategy Officer and SVP, WW Licensing & External Research
Merck and Company
Thomas Hofstaetter
SVP, Corporate Business Development
Wyeth
Jean-Luc Belingard
Chairman &
CEO
Ipsen
Judith Hills
Vice President, Asia Pacific, Japan and Emerging Markets R&D
Glaxosmithkline
Andrew Dillon
CEO National Institute for Health and Clinical Excellence
NICE
Dr. Lauren Silverman
Novartis Option Fund
Peter Mueller, PhD
Executive Vice President, Global Research and Development, and Chief Scientific
Officer
Vertex Pharmaceuticals |
Benchmark your corporate strategies against the best and the brightest.
Can You Be Big and Small at Once?
For at least two decades now, Big Pharma has believed in the value of big. But
they’ve also seen its downside: bureaucratic paralysis, the burden of growing a
substantial top-line, cultural stagnation. And so a number of companies are now
trying to have their cake and eat it, too: adding capabilities (through
acquisitions) and diversifications while creating therapeutically- or
market-focused units capable of making and executing their own investment
decisions independent of the mother ship). This way they’ll have the advantages
of being big (the financial strength to survive major research and commercial
blows, the infrastructure to globally develop and commercialize new
opportunities) and small (speed, focus and entrepreneurial excitement). The 19th
annual PSA will explore the implications and inherent contradictions of this new
bifurcated strategy, how and why companies are pursuing it (or not pursuing it)
and its likely effects on biotech and on dealmaking in general.
Who will you meet?

-
Meet your potential partner and find out how to approach them
Meet your potential partner and find out how to approach them
-
Understand externalization models and see if your approach fits your potential partner's positioning
-
Benchmark your dealmaking strategy against what your competitors are doing and why
-
Learn the deal values and deal specifics that let you calibrate deal-making metrics
Maximize your strategic alliance opportunities by hearing CEOs, senior R&D and senior business development executives share lessons learned, practical advice and strategies on how to build your R&D pipeline – both internally and externally. Take away the newest strategies and tactics that you can apply to your company’s dealmaking efforts immediately!
And this September, PSA offers you an unbeatable line-up of Big Pharma and biotech speakers to forecast trends and analyze changes in alliances and M&A. You’ll hear from, and be able to quiz, top industry executives and dealmakers.
PSA gathers top thinkers to grapple with the fundamental challenges facing biotech and pharma – equipping dealmakers like you with the insights, information and practical advice you'll need to strike successful deals. This program will sell out so register early. Space is limited, so register today!
BEYOND THE BASICS! Windhover is proud to present the ONLY conference that delivers 100% case studies by CEOs and senior executives in the industry.
What your colleagues and competitors have to say about Pharmaceutical Strategic Alliances:
"Overall, I was pleasantly surprised. It was an excellent meeting and
exceeded my expectations because of the quality of attendees."
"I appreciate Windhover conferences. Your organization is one of the few that is
trying to understand the pharma/biotech industry in a strategic context."
"I attend every year. The content is always
engaging."
"One of the 'most attended' conferences, as always."
"One of the conferences that I learn something of value."
"It was very good, the presentations and networking opportunities were
excellent."
"Definitely worthwhile. Speakers focused on topics and insights, not on company
promotion."
"Excellent topic coverage, as well as representation of speakers."
"The entire agenda is well thought-out and covers several very pertinent
topics."
"Great chance to network with leading business development professionals in the
industry and share collaboration ideas."
"A good review of what is going on at the pharma and biotech industries with a
brilliant strategic analysis. Excellent selection of speakers and participants
at the roundtable discussions."
|
|
|
 |
|
|
|
|
| |
 |
Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. . . [MORE] (IN VIVO)
The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. . . [MORE] (Start-Up)
Stent Market Doldrums Push Interest Elsewhere
The new realities of the drug-eluting stent market are evident in recent sales results from the big competitors, driving many of them to branch into other higher growth areas. . . [MORE] (Medtech Insight)
The Future of Pharma: The Scale to Fail
The pharmaceutical sector saw a wave of major consolidation in 2009. There are a number of lessons to be learned from the M&A activity that can be applied to the New Year, including the increasing need to get bigger in order to absorb the R&D misses. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|